Загрузка...
Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
SIMPLE SUMMARY: The lung immune prognostic index (LIPI) is proposed as a simple risk scoring tool to differentiate differences in survival from immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC). The tool has not been evaluated for performance in a NSCLC cohort initia...
Сохранить в:
| Опубликовано в: : | Cancers (Basel) |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7967121/ https://ncbi.nlm.nih.gov/pubmed/33803256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13051176 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|